Effects of VEGF temporal and spatial presentation on angiogenesis.

Therapeutic angiogenesis relies on the delivery of angiogenic factors capable of reversing tissue ischemia. Polymeric materials that can provide spatial and temporal over vascular endothelial growth factor (VEGF) presentation provide clear benefit, but the influence of VEGF dose, temporal, and spatial presentation on the resultant angiogenic process are largely unknown. The influence of the temporal profile of VEGF concentration, dose, and the impact of VEGF spatial distribution on angiogenesis in in vitro models of angiogenesis and ischemic murine limbs was analyzed in this study. Importantly, a profile consisting of a high VEGF concentration initially, followed by a decreasing concentration over time was found to yield optimal angiogenic sprouting. A total VEGF dose 0.1 microg/g, when delivered with kinetics found to be optimal in vitro, provided a favorable therapeutic dose in murine hindlimb ischemia model, and distributing this VEGF dose in two spatial locations induces a higher level of vascularization and perfusion than a single location. These findings suggest that material systems capable of controlling and regulating the temporal and spatial presentation of VEGF maybe useful to achieve a robust and potent therapeutic angiogenic effect in vivo.

[1]  Eben Alsberg,et al.  Degradation of Partially Oxidized Alginate and Its Potential Application for Tissue Engineering , 2001, Biotechnology progress.

[2]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[3]  K. Lee,et al.  Local and Sustained Vascular Endothelial Growth Factor Delivery for Angiogenesis Using an Injectable System , 2009, Pharmaceutical Research.

[4]  J. Isner,et al.  Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. , 1999, Circulation.

[5]  R. Stouffer,et al.  Isolation and culture of microvascular endothelial cells from the primate corpus luteum. , 1996, Biology of reproduction.

[6]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[7]  H. Blau,et al.  Critical role of microenvironmental factors in angiogenesis , 2005, Current atherosclerosis reports.

[8]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[9]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[10]  Christopher C W Hughes,et al.  VEGF121 and VEGF165 Regulate Blood Vessel Diameter Through Vascular Endothelial Growth Factor Receptor 2 in an in vitro Angiogenesis Model , 2003, Laboratory Investigation.

[11]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[12]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[13]  David J Mooney,et al.  Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. , 2005, Biomaterials.

[14]  D J Mooney,et al.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis , 2007, Journal of thrombosis and haemostasis : JTH.

[15]  G. Conn,et al.  Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Place,et al.  Complexity in biomaterials for tissue engineering. , 2009, Nature materials.

[17]  David J Mooney,et al.  Temporally regulated delivery of VEGF in vitro and in vivo. , 2006, Journal of biomedical materials research. Part A.

[18]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[19]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[20]  David J Mooney,et al.  Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. , 2007, Cardiovascular research.

[21]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[22]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[23]  R. Sainson,et al.  Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. , 2003, Microvascular research.

[24]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[25]  Jeffrey A. Hubbell,et al.  Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.

[26]  I. Hoefer,et al.  Experimental models of arteriogenesis: differences and implications , 2006, Lab Animal.

[27]  M. Merchant,et al.  Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[29]  David J. Mooney,et al.  Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.

[30]  David J Mooney,et al.  Integrated approach to designing growth factor delivery systems , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.